The Nanotechnology Revolution: Are FDA and the Public Ready for It?
by Edward John Allera, Partner in the law firm of Buchanan Ingersoll & Rooney PC, Washington, DC

and

William A. Garvin, Associate in the law firm of Buchanan Ingersoll & Rooney PC, Washington, DC

Nanotechnology in Cosmetics: Where Beauty Meets Regulation
by Ellen Maldonado, Attorney and Sole Practitioner

Nanotechnology in Foods: Its Impact Could Be ‘Large’
by Ray A. Matulka, staff toxicologist at the Burdock Group, a toxicology consulting firm located in Vero Beach, FL and Washington, DC

and

James C. Griffiths, Senior Toxicologist and Director at the Burdock Group, a toxicology consulting firm located in Vero Beach, FL and Washington, DC

Regulating Nanotechnology: What FDA Can Borrow from a Sister Agency
by Susan D. Brienza, Of Counsel in the law firm of Patton Boggs LLP, Denver, CO

Risk Mitigation Strategies For Manufacturers of Nanomaterials
by Antony Klapper, Partner in the Partner Products Liability Group in the law firm of Reed Smith LLP, Washington, DC

and

Ricardo Carvajal, Of Counsel in the Health Care Group in the law firm of Reed Smith LLP, Washington, DC

and

Jesse Ash, Associate in the Products Liability Group in the law firm of Reed Smith LLP, Washington, DC

Dietary Supplement GMPs…and the Conundrum That Is DSHEA
by I. Scott Bass, head of the Global Life Sciences Team in the law firm of
Sidley Austin LLP

Regulating Biotech Foods in U.S. and Europe: Promoting Public Health
or Harm?
by Mark I. Schwartz, Associate Chief Counsel of the Food and Drug Administration

Pharmaceutical Patents After KSR: Withstanding the Obviousness Challenge
by Esther H. Steinhauer, Counsel in the law firm of Hunton & Williams LLP,
New York, NY

History Corner
Celebrating a Milestone: FDA’s Approval of First Genetically-Engineered Product
By Suzanne White Junod, Historian with the Food and Drug Administration,
Rockville, MD

Enforcement Corner
The OxyContin Case – Something for Everyone
by John R. Fleder, a Principal in the law firm of Hyman, Phelps & McNamara, P.C., Washington, DC

Global Corner
Nanotechnology: At Risk from Poor Regulation?
by Matthew R. Weinberg, Chief Executive Officer, THE WEINBERG GROUP, Washington, DC

Canadian Corner
Health Canada Reviews Changes to Clinical Trial Regulations
by Brian Daley, Partner in the law firm of Ogilvy Renault in Montreal, Quebec, Canada

Associates’ Corner
Citizen Petition Reform: Preventing Delays of Generic Drug Applications
by Melissa L. Paddock, Associate with the law firm of Goodwin Procter LLP,
Boston, MA

(Note: All author affiliations are current as of the date of publication of the issue.)